Related Experiment Videos
[Linezolid, the first oxazolidinone antibiotic]
H Dutronc1, F Bocquentin, T Galpérine
1Fédération de maladies infectieuses, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. herve.dutronc@chu-bordeaux.fr
Medecine Et Maladies Infectieuses
|November 22, 2005
Summary
Multiresistant bacteria necessitate novel antibiotics like linezolid, an oxazolidinone. This review covers its antibacterial activity, pharmacokinetics, and use in treating serious Gram-positive infections.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Context:
- Rising prevalence of multidrug-resistant Staphylococcus and Enterococcus strains.
- Need for novel therapeutic agents to combat resistant bacterial infections.
Purpose:
- To provide a comprehensive review of linezolid, a first-in-class oxazolidinone antibiotic.
- To detail its antibacterial spectrum, pharmacokinetic profile, and clinical applications.
Summary:
- Linezolid exhibits potent activity against Gram-positive bacteria, including resistant strains.
- Its pharmacokinetic properties support efficacy in treating serious infections like pneumonia and skin infections.
- The review outlines administration guidelines and tolerability for effective clinical use.
Impact:
- Linezolid offers a crucial therapeutic option against challenging Gram-positive pathogens.
- Understanding its properties aids clinicians in optimizing treatment strategies.
- Contributes to the management of infections caused by multidrug-resistant organisms.